Inventor · disambiguated record
Charleen Hunt
Also filed as: HUNT CHARLEEN
7 granted patents·7 pending applications·8 citations·filing 2015–2023
77Inventor score
Files withREGENERON PHARMA14
Top patents by PatentIndex Score
14 records- 0187US11519004B2Transcription modulation in animals using CRISPR/Cas systemsREGENERON PHARMA·Filed 2019·Granted Dec 6, 2022·4 cites·35 claims
- 0280US11470828B2Rodent model of mood disordersREGENERON PHARMA·Filed 2020·Granted Oct 18, 2022·1 cites·24 claims
- 0380US11130999B2Cas-ready mouse embryonic stem cells and mice and uses thereofREGENERON PHARMA·Filed 2018·Granted Sep 28, 2021·1 cites·36 claims
- 0480US10548302B2Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophyREGENERON PHARMA·Filed 2017·Granted Feb 4, 2020·1 cites·30 claims
- 0579US11021719B2Methods and compositions for assessing CRISPER/Cas-mediated disruption or excision and CRISPR/Cas-induced recombination with an exogenous donor nucleic acid in vivoREGENERON PHARMA·Filed 2018·Granted Jun 1, 2021·1 cites·30 claims
- 0678US2024093316A1Cas-ready mouse embryonic stem cells and mice and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 0773US11866794B2Cas-ready mouse embryonic stem cells and mice and uses thereofREGENERON PHARMA·Filed 2021·Granted Jan 9, 2024·0 cites·18 claims
- 0870US2023123787A1Rodent model of mood disordersREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 0968US11730150B2Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophyREGENERON PHARMA·Filed 2019·Granted Aug 22, 2023·0 cites·20 claims
- 1063US2016060657A1Methods and compositions for the targeted modification of a genomeREGENERON PHARMA·Filed 2015·Application pending·0 cites
- 1163US2021261985A1Methods and compositions for assessing crispr/cas-mediated disruption or excision and crispr/cas-induced recombination with an exogenous donor nucleic acid in vivoREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 1254US2021079394A1Transcription modulation in animals using crispr/cas systems delivered by lipid nanoparticlesREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 1351US2019032156A1Methods and compositions for assessing crispr/cas-induced recombination with an exogenous donor nucleic acid in vivoREGENERON PHARMA·Filed 2018·Application pending·0 cites
- 1448US2023102342A1Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of useREGENERON PHARMA·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Charleen Hunt files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →